中国医学创新
中國醫學創新
중국의학창신
Medical Innovation of China
2015年
31期
128-129
,共2页
长效单药抗高血压%短效联合抗高血压%收缩压变异性
長效單藥抗高血壓%短效聯閤抗高血壓%收縮壓變異性
장효단약항고혈압%단효연합항고혈압%수축압변이성
Long-acting antihypertensive monotherapy%Short-acting antihypertensive joint%Systolic blood pressure variability
目的：分析长效单药联合短效行抗高血压的临床疗效，并观察患者在随诊期间收缩压变化。方法：选取本院自2012年12月-2013年12月收治的60例接受抗高血压患者，采取随机数字表法分为长效单药组与短效联合组，每组各30例，观察两组患者治疗后收缩压变化情况。结果：长效单药组基线收缩压为（148.7±17.8）mm Hg，短效联合组基线收缩压为（143.5±16.9）mm Hg，两组比较差异无统计学意义（t=1.67， P>0.05）。长效单药组收缩压下降值为（11.3±6.5）mm Hg，收缩压标准差为（8.6±3.6）mm Hg；短效联合组收缩压下降值为（9.4±15.4）mm Hg，收缩压标准差为（7.5±4.1）mm Hg，两组比较差异无统计学意义（P<0.05）。结论：长效单药较短效联合用药在抗高血压治疗方面具有突出的临床优势，可有效降低随诊期间患者收缩压，值得推广与应用。
目的：分析長效單藥聯閤短效行抗高血壓的臨床療效，併觀察患者在隨診期間收縮壓變化。方法：選取本院自2012年12月-2013年12月收治的60例接受抗高血壓患者，採取隨機數字錶法分為長效單藥組與短效聯閤組，每組各30例，觀察兩組患者治療後收縮壓變化情況。結果：長效單藥組基線收縮壓為（148.7±17.8）mm Hg，短效聯閤組基線收縮壓為（143.5±16.9）mm Hg，兩組比較差異無統計學意義（t=1.67， P>0.05）。長效單藥組收縮壓下降值為（11.3±6.5）mm Hg，收縮壓標準差為（8.6±3.6）mm Hg；短效聯閤組收縮壓下降值為（9.4±15.4）mm Hg，收縮壓標準差為（7.5±4.1）mm Hg，兩組比較差異無統計學意義（P<0.05）。結論：長效單藥較短效聯閤用藥在抗高血壓治療方麵具有突齣的臨床優勢，可有效降低隨診期間患者收縮壓，值得推廣與應用。
목적：분석장효단약연합단효행항고혈압적림상료효，병관찰환자재수진기간수축압변화。방법：선취본원자2012년12월-2013년12월수치적60례접수항고혈압환자，채취수궤수자표법분위장효단약조여단효연합조，매조각30례，관찰량조환자치료후수축압변화정황。결과：장효단약조기선수축압위（148.7±17.8）mm Hg，단효연합조기선수축압위（143.5±16.9）mm Hg，량조비교차이무통계학의의（t=1.67， P>0.05）。장효단약조수축압하강치위（11.3±6.5）mm Hg，수축압표준차위（8.6±3.6）mm Hg；단효연합조수축압하강치위（9.4±15.4）mm Hg，수축압표준차위（7.5±4.1）mm Hg，량조비교차이무통계학의의（P<0.05）。결론：장효단약교단효연합용약재항고혈압치료방면구유돌출적림상우세，가유효강저수진기간환자수축압，치득추엄여응용。
Objective:To explore and analyze long-term line of single-drug combination of short-acting antihypertensive clinical efficacy, and systolic blood pressure were observed in patients during the follow-up impact of variability.Method: In our hospital from December 2012 to December 2013 were treated 60 patients with anti-hypertensive, and they were randomly divided into long-term monotherapy with short-acting combination group, 30 cases in each group, and observe after treatment systolic blood pressure changes.Result: The long-term monotherapy baseline systolic pressure (148.7±17.8) mm Hg, short-acting combination group for baseline systolic blood pressure (143.5±16.9) mm Hg, no significant difference between the two groups (t=1.67,P>0.05). Long-term value of systolic blood pressure decreased monotherapy group (11.3±6.5) mm Hg, systolic blood pressure standard deviation (8.6±3.6) mm Hg, systolic blood pressure decreased short-acting combined group was (9.4±5.4) mm Hg, systolic blood pressure and standard deviation (7.5±4.1) mm Hg, compared to the difference between the two groups was significant (P<0.05).Conclusion:The long-term effect of combination therapy monotherapy short of outstanding clinical advantage in terms of anti-hypertensive therapy, can effectively reduce systolic blood pressure of patients during the follow-up, worthy of promotion and application.
